P2Y12 Inhibitor or Aspirin Monotherapy for Secondary Prevention of Coronary Events.
Gragnano F, Cao D, Pirondini L, Franzone A, Kim HS, von Scheidt M, Pettersen AR, Zhao Q, Woodward M, Chiarito M, McFadden EP, Park KW, Kastrati A, Seljeflot I, Zhu Y, Windecker S, Kang J, Schunkert H, Arnesen H, Bhatt DL, Steg PG, Calabrò P, Pocock S, Mehran R, Valgimigli M; PANTHER Collaboration.
Gragnano F, et al. Among authors: arnesen h.
J Am Coll Cardiol. 2023 Jul 11;82(2):89-105. doi: 10.1016/j.jacc.2023.04.051.
J Am Coll Cardiol. 2023.
PMID: 37407118
BACKGROUND: Aspirin is the only antiplatelet agent with a Class I recommendation for long-term prevention of cardiovascular events in patients with coronary artery disease (CAD). ...CONCLUSIONS: Given its superior efficacy and similar overall safety, P2Y(12) inhibitor mono …
BACKGROUND: Aspirin is the only antiplatelet agent with a Class I recommendation for long-term prevention of cardiovascular events in …